-
Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial
CONCLUSIONS: The results of the FIRST-NIS support Rd as an effective and safe frontline treatment option for patients with TIE NDMM, irrespective of age, with similar clinical outcomes in the real world compared to the pivotal trial. →
-
Long-term brain pressure monitoring via a discrete microimplant; a first-in-human safety and initial efficacy trial in adults and children with hydrocephalus
Emerging neurotechnologies such as brain-computer interfaces and implantable sensors offer considerable promise in the treatment of a broad range of neurological conditions. The key challenges are reducing the implant size, powering it, and confirming long-term accuracy and safety. Here we report the development of a novel type of implantable medical device that measures intracranial pressure… →
-
Advancing neonatal jaundice screening with mHealth: a mixed-methods randomised controlled feasibility study in a resource-limited setting in Mexico
CONCLUSIONS: Implementing Picterus Jaundice Pro yielded encouraging improvements in screening practices, underscoring its potential to advance neonatal care. Addressing systemic barriers and raising awareness among parents and healthcare workers is crucial for maximizing impact. →
-
Double-blind randomized control trial investigating immediate changes in pain processing measures in response to dry needling to the lumbar multifidus in an asymptomatic population
CONCLUSION: A significant main effect was observed in response to DN and sham DN local to the intervention site. This finding suggests peripherally mediated shared mechanisms between DN and sham DN. Baseline pain modulatory efficiency and post-intervention expectations may be indicators of individuals who will experience a greater analgesic response to needling interventions. →
-
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
BACKGROUND: [^(177)Lu]Lu-prostate-specific membrane antigen (PSMA)-617 (^(177)Lu-PSMA-617) is a novel treatment for metastatic castration-resistant prostate cancer. Here, we aimed to evaluate ^(177)Lu-PSMA-617 in patients with PSMA-expressing oligometastatic hormone-sensitive prostate cancer (HSPC). →
-
Job Pivots in the Age of AI: Lessons From Mike Mulligan and His Steam Shovel
Matt Harrison Clough As organizations like Amazon, PwC, and Microsoft have announced AI-fueled layoffs, it’s no surprise that half of Americans have expressed concern about AI’s larger potential impact on their jobs. Of course, companies can attribute layoffs to AI efficiencies while trimming workforces for various reasons. Yet there is no question that artificial intelligence… →
-
The Founder of OpenCV Is Speaking at OSCCA, Don’t Miss It!
Over 1.5 billion downloads. Used in everything from self-driving cars to medical imaging to robotics. OpenCV has become the backbone of modern computer vision — and it all started with one person. Gary Bradski, the founder of OpenCV, is coming to OSCCA, the OpenCV-SID Conference on Computer Vision & AI, on May 4th in Los… →
-
Comparative analysis of postoperative pain following bioceramic sealer application with three obturation methods: A randomized controlled trial
CONCLUSIONS: The sealer-based and hot modified methods significantly reduced postoperative pain compared to traditional techniques. These findings support the clinical adoption of innovative bioceramic sealer techniques to optimize pain management and patient satisfaction. →
-
Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction
Aim To evaluate the impact of digital remote monitoring on the effectiveness of intensive dose titration for guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) for the achievement of target doses and the reduction of decompensated heart failure rate and all-cause mortality.Materials and methods The study utilized vital sign… →
-
Novel application for the JAK inhibitor baricitinib in the treatment of Vogt-Koyanagi-Harada disease: a prospective cohort study
CONCLUSION: This study demonstrates that baricitinib is a promising therapeutic option for both early- and late-stage VKH disease. It effectively controls choroidal inflammation, improves visual function, and allows for a substantial reduction in corticosteroid burden with a favorable safety profile. →
